Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Parthasarathy, HK; Pieske, B; Weisskopf, M; Andrews, CD; Brunel, P; Struthers, AD; MacDonald, TM.
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction
Eur J Heart Fail. 2009; 11(10):980-989
Doi: 10.1093/eurjhf/hfp120
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Pieske Burkert Mathias
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aims To determine whether valsartan improves treadmill exercise time, in patients with symptomatic heart failure with a preserved ejection fraction (HFPEF), compared with placebo. Methods and results In this multicentred, double-blind, 14-week study, patients were randomized to receive valsartan (V) 80 mg or placebo (P) once daily on top of background medications. The dose of valsartan was force-titrated up to 320 mg. A total of 152 patients were randomized (V = 70, P = 82). Most patients had well-controlled hypertension (V = 91.2%, P = 89.0%) (mean baseline systolic BP similar to 130 mmHg) and >50% were receiving an angiotensin-converting enzyme inhibitor and/or beta-blocker (V = 57.4%, P = 54.9%). The mean ejection fraction at baseline was 70.48% in the placebo group (n = 64) and 71.52% in the valsartan group (n = 79). Valsartan had no significant effect on exercise time (primary variable), gas exchange variables, 6 min walk test distance, exertion-related symptoms, brain natriuretic peptide levels, echocardiographic parameters, or quatity-of-life scores. Valsartan significantly lowered peak exercise systolic BP (-13.1 mmHg vs. placebo; P < 0.001) and improved ratings of perceived exertion (Borg score) (-0.69 vs. placebo; P = 0.008). Conclusion In this population, which predominantly included patients with well-controlled hypertension and symptomatic HFPEF, addition of valsartan did not increase exercise time within 14 weeks. However, valsartan 320 mg reduced blood pressure and improved symptoms of perceived exertion (Borg score) during exercise and was generally well-tolerated.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Angiotensin II Type 1 Receptor Blockers - administration and dosage
- Dose-Response Relationship, Drug -
- Double-Blind Method -
- Drug Administration Schedule -
- Exercise Tolerance - drug effects
- Female -
- Follow-Up Studies -
- Heart Failure - diagnosis Heart Failure - drug therapy Heart Failure - mortality
- Humans -
- Male -
- Middle Aged -
- Multivariate Analysis -
- Risk Assessment -
- Severity of Illness Index -
- Statistics, Nonparametric -
- Stroke Volume - drug effects
- Survival Analysis -
- Tetrazoles - administration and dosage
- Treatment Outcome -
- Valine - administration and dosage Valine - analogs and derivatives
- Find related publications in this database (Keywords)
- Heart failure with preserved ejection fraction
- Echocardiography
- Exercise time
- Placebo
- Quality of life
- Valsartan